STOCK TITAN

Microbot Medical, Inc. - MBOT STOCK NEWS

Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.

Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.

One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.

Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.

Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.

Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.

For further information about Microbot Medical, please visit www.microbotmedical.com.

Rhea-AI Summary

Microbot Medical Inc. (Nasdaq: MBOT) has received a new patent allowance for its LIBERTY® Robotic System from the Israeli Patent Office, complementing a prior grant in the U.S. This patent covers the system's unique modular design, reinforcing its position as a leader in fully disposable robotic systems for endovascular procedures. CEO Harel Gadot highlighted the achievement of five patents for the system since its launch three years ago, emphasizing its potential to improve patient access to advanced treatments. The company is now entering regulatory phases and commercialization plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) bolsters its Scientific Advisory Board (SAB) with the addition of Dr. Thierry Jacques De Baère, renowned head of the Interventional Radiology Unit at Institut Gustave Roussy in France. The SAB now includes 11 leading experts from the U.S., Europe, and Israel, enhancing support for the LIBERTY® Robotic System. This system, the first fully disposable robotic platform for endovascular procedures, aims to advance regulatory and commercialization goals. Dr. De Baère praises LIBERTY's reliability and ease of use, indicating strong potential for improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
management
-
Rhea-AI Summary

Microbot Medical Inc. (Nasdaq: MBOT) has completed a registered direct offering with an institutional investor, raising approximately $5 million. The offering involved 1,022,495 common shares sold at $4.89 each, including pre-funded warrants. Concurrently, the company issued unregistered series A and B preferred investment options. The funds will support the development and commercialization of the LIBERTY® Robotic System, among other uses. H.C. Wainwright & Co. acted as the placement agent for these offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) announced a definitive agreement to sell 1,022,495 shares of common stock at $4.89 per share, generating approximately $5 million in gross proceeds. The offering includes pre-funded warrants for 240,000 shares and options for the purchase of additional shares at $4.64 each. The net proceeds will fund the development of the LIBERTY® Robotic System and other corporate purposes. The transaction is slated to close around October 25, 2022, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
-
Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) has submitted a follow-up pre-submission package for its LIBERTY® Robotic System, aiming for alignment with the FDA as it prepares for an Investigational Device Exemption (IDE) submission and a first-in-human clinical trial in 2023. The company has reported constructive engagement with the FDA, which is seen as encouraging for their upcoming regulatory steps. The LIBERTY system is part of Microbot's multi-generation portfolio focused on advanced micro-robotic technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Summary

Microbot Medical Inc. (Nasdaq: MBOT) has completed a significant GLP animal study for its LIBERTY® Robotic System, the first disposable robotic system aimed at endovascular procedures. Conducted at a top MedTech research lab, the study achieved a successful navigation rate of 92% for the robotic system, while demonstrating no evidence of acute vascular injury. Physicians graded the LIBERTY system highly for usability, indicating a quick setup and easy learning curve. However, the LIBERTY Robotic System is still investigational and has not yet received FDA clearance for use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
Rhea-AI Summary

Microbot Medical Inc. (Nasdaq: MBOT) has suspended the development of its Self-Cleaning Shunt (SCS) project to focus on the LIBERTY® Robotic System. This strategic shift follows positive developments, including the acquisition of endovascular assets from Nitiloop Ltd. and plans for a First-in-Human trial. The company will explore opportunities for the SCS assets, such as licensing or joint ventures. Microbot is on track with key milestones for the LIBERTY system through 2023, aiming to enhance shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
none
-
Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) announced a new patent allowance from the Israeli Patent Office for its LIBERTY® Robotic System, specifically covering its roll assembly mechanism. This expansion of the intellectual property portfolio underscores the company's commitment to developing innovative micro-robotic technologies aimed at improving patient care accessibility. CEO Harel Gadot emphasized the importance of these capabilities in realizing their vision of disposable robotics that enhance healthcare worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) has acquired the assets of Nitiloop Ltd., which includes the FDA-cleared NovaCross™ family of microcatheters. This acquisition aims to enhance the LIBERTY® Robotic System's capabilities, promoting robotics in endovascular procedures. The NovaCross™ devices are designed for navigating chronic total occlusions (CTO) and will potentially standardize procedures while increasing access to robotic technology globally. The move opens a significant growth opportunity in the $500 million CTO market, aligning with Microbot's strategic mission for global accessibility in medical technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
Rhea-AI Summary

Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of Dr. David C. Madoff to its Scientific Advisory Board. Dr. Madoff, a renowned interventional radiologist from Yale School of Medicine, brings extensive clinical research experience that is expected to enhance the company's efforts in advancing the LIBERTY® Robotic System through regulatory phases. His expertise in interventional oncology and numerous publications position him to significantly contribute to Microbot's mission of improving clinical outcomes and accessibility in healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
management

FAQ

What is the current stock price of Microbot Medical (MBOT)?

The current stock price of Microbot Medical (MBOT) is $0.9745 as of December 20, 2024.

What is the market cap of Microbot Medical (MBOT)?

The market cap of Microbot Medical (MBOT) is approximately 16.6M.

What is Microbot Medical, Inc.?

Microbot Medical, Inc. is a pre-clinical medical device company specializing in developing next-generation micro-robotic medical technologies for minimally invasive procedures.

What is the LIBERTY Endovascular Robotic Surgical System?

The LIBERTY Endovascular Robotic Surgical System is an innovative platform aimed at improving endovascular procedures by eliminating the need for large, cumbersome equipment while reducing radiation exposure and physician strain.

What recent achievements has Microbot Medical accomplished?

Microbot Medical recently achieved positive results from its pivotal GLP pre-clinical study and submitted an IDE application to the FDA, paving the way for its first human clinical trials.

What are the core technologies developed by Microbot Medical?

Microbot Medical's core technologies include the Virob platform, an autonomous advancing micro-robot, and the LIBERTY Endovascular Robotic Surgical System.

What is the vision of Microbot Medical?

Microbot Medical aims to transform minimally invasive surgeries by providing cutting-edge micro-invasive technologies that help physicians target disease sites with unmatched precision.

How is Microbot Medical preparing for commercialization?

Microbot Medical is engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for its technologies once regulatory approvals are obtained.

What impact do recent geopolitical events have on Microbot Medical's operations?

Despite recent geopolitical events in Israel, Microbot Medical's operations in Israel, the USA, and other parts of the globe remain uninterrupted, and the company believes it will achieve its regulatory and commercial milestones as scheduled.

What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?

The Self-Cleaning Shunt (SCS) is another innovative platform developed by Microbot Medical aimed at improving the quality of life for patients by providing less invasive and more precise solutions for surgical procedures.

Who is acting as the exclusive placement agent for Microbot Medical's offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for Microbot Medical's offering.

How can I get more information about Microbot Medical?

For more information about Microbot Medical, you can visit their website at www.microbotmedical.com.

Microbot Medical, Inc.

Nasdaq:MBOT

MBOT Rankings

MBOT Stock Data

16.59M
16.69M
1.43%
7.46%
3.43%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
HINGHAM